Roche’s Rituxan biosimilar woes are just beginning
Last week, Roche filed a Worker Adjustment and Retraining Notification to the State...
Trending:
-
![]()
After Zavante deal, Nabriva is poised to launch two first-in-class antibiotics
-
![AbbVie]()
AbbVie poised to overtake Gilead as hepatitis C leader
-
![medicine]()
The FDA’s approach to tackling injectable drug shortages
-
![Pillpack]()
Amazon set to acquire PillPack and disrupt healthcare
-
![]()
Are US pharma companies immune to US–Canada trade wars?
-
![]()
A formula for success: inside Swiss pharma
Most Read
- Oxford Genetics signs agreement for CRISPR cell lines with global e-commerce company
- AbbVie poised to overtake Gilead as hepatitis C leader
- The FDA’s approach to tackling injectable drug shortages
- J&J collaborates with Merck to launch diabetes drug in China
- Salix to co-promote first approved non-opioid for opioid withdrawal
Latest Content
Allergan to buy neurotoxins firm Bonti for $195m
Allergan has entered an agreement to acquire biotechnology company Bonti for an upfront payment of $195m along with other potential commercial milestone-based payments.
Boehringer exercises option to buy ViraTherapeutics for $245m
Boehringer Ingelheim has acquired all of the shares in biopharmaceutical firm ViraTherapeutics for €210m ($245m) based on an option and share purchase agreement signed with EMBL Ventures in August 2016.
Novartis to divest select Sandoz US portfolio to Aurobindo for $900m
Novartis has signed an agreement to sell parts of its Sandoz US business to Aurobindo Pharma USA for a cash consideration of $900m, along with potential earn-outs worth $100m.
LEO Pharma closes Bayer’s prescription dermatology unit deal in US
LEO Pharma has completed the acquisition of Bayer’s prescription dermatology portfolio in the US, with closing in other markets expected in the second half of next year.
Evox Therapeutics raises new funds to support drug development
UK-based therapeutics developer Evox Therapeutics has secured $45.4m in a series B financing round led by Redmile Group to support new drug development.
Shire divests oncology business to Servier for $2.4bn
Shire has concluded the divestiture of its Oncology unit to French pharmaceutical company Servier for a total consideration of $2.4bn.
Emergent BioSolutions to acquire Adapt Pharma for up to $735m
Emergent BioSolutions has agreed to acquire Ireland-based Adapt Pharma for an upfront payment of $635m, followed by up to $100m in potential sales-based milestones through 2022.
August’s top news stories
Novo Nordisk acquired 100% of shares in UK-based biotechnology firm Ziylo under a potential deal worth more than $800m, and a new pre-clinical study at the University of Pennsylvania showed the potential of a universal flu vaccine candidate in protecting against different strains. Pharmaceutical-technology.com wraps up the key headlines from August 2018.
Roche’s Rituxan biosimilar woes are just beginning
Last week, Roche filed a Worker Adjustment and Retraining Notification to the State of California’s Employment Development Department, citing plans to lay off 223 employees at its Genentech site.
TraceLink secures new funds to digitalise pharmaceutical supply chain
TraceLink has received new funding to support its effort to expand the real-time information-sharing network in order to digitalise the global pharmaceutical supply chain.
Latest News
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.
